Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dendritic cell + cytokine-induced killer cell therapy + MUC1 peptide
- Development stage
- Unknown
- Lead developer
- Cancer Institute of the People's Liberation Army, Third Military Medical University
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Peptides
- Administration
- Intravenous
01
Overview
Dendritic cell + cytokine-induced killer cell therapy + MUC1 peptide is an experimental autologous cellular immunotherapy. The treatment process involves harvesting patient-derived dendritic cells (DCs) and loading them with MUC1 (Mucin-1) peptide antigens. These antigen-loaded DCs are then co-cultured with cytokine-induced killer (CIK) cells to prime and activate them against tumor cells expressing the MUC1 antigen. This combined cell population is then re-infused into the patient to generate a targeted immune response. Developed by the Cancer Institute of People's Liberation Army and Third Military Medical University Xinqiao Hospital, it is primarily investigated for the treatment of middle or terminal stage non-small-cell lung cancer (NSCLC), often in combination with radiotherapy to enhance clinical efficacy.
- Other names
- MUC1-DC-CIKMUC-1-DC-CIKMUC 1-DC-CIKMUC1 peptide-loaded dendritic cell and cytokine-induced killer cell therapyMUC-1 peptide-loaded dendritic cell and cytokine-induced killer cell therapyMUC 1 peptide-loaded dendritic cell and cytokine-induced killer cell therapy
02
Targets
MICB (Major histocompatibility complex class i-related protein B)MUC1-pMHC (Mucin 1 peptide–Major Histocompatibility Complex)MUC1-MHC (Mucin 1 peptide–Major Histocompatibility Complex)TA-MUC1-pMHC (Tumor-associated Mucin 1 peptide-MHC complex)
Beyond the preview
Go deeper on dendritic cell + cytokine-induced killer cell therapy + MUC1 peptide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dendritic cell + cytokine-induced killer cell therapy + MUC1 peptide.